Modeling of the in vivo kinetics of antioxidants delineates suitable parameters for selecting potential antioxidant adjuvants for cancer therapy.
To find in vivo behaviors of an antioxidant when used as an adjuvant cancer therapy, a more detailed integrated pharmacokinetic scheme is needed. Major reaction parameters associated with the sequential routes from ingestion to decay of an antioxidant were used in mathematical analysis, which included absorption rate coefficient k(a), quenching rate coefficient of the antioxidant k(q1) and tissue quenching rate coefficient k(r). The model was then treated with computer simulation using cited decay rate coefficients and some assumed parameters. When intestinal absorption rate coefficient k(a) becomes larger, retention time of antioxidant in plasma would be prolonged. moreover, k(a) had no effect on either quenching ability of antioxidants or tissue recovering capability. in quenching plasma ROS, the larger the quenching coefficient k(q1), the shorter peak- and the life-times would be for the secondary free radicals that are formed in primary quenching. Conclusively, it is suggestive to prescribe an antioxidant therapy with an appropriate values of k(a) and larger values of k(q1).
Yang
Ming-Hua
MH
Department of Food and Nutrition, Hungkuang University, Shalu County, Taichung Hsien, Taiwan.
Chuang
Chao-Ming
CM
Hsieh
Chiu-Lan
CL
Wang
Hui-Er
HE
Chen
Kuan-Chou
KC
Chiu
Wen-Ta
WT
Shih
Chun-Ming
CM
Peng
Robert Y
RY
D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000975:Antioxidants / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002338:Carotenoids / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D000529:Complementary Therapies; D003198:Computer Simulation; D019587:Dietary Supplements; D006207:Half-Life; D006801:Humans; D007408:Intestinal Absorption; D000077276:Lycopene; D008353:Mannitol / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D008954:Models, Biological; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D017382:Reactive Oxygen Species / Q000097:blood / Q000737:chemistry
D000970:Antineoplastic Agents; D000975:Antioxidants; D017382:Reactive Oxygen Species; D002338:Carotenoids; D008353:Mannitol; D000077276:Lycopene